

APPENDIX S – Summary of Changes 2021

The 2021 FCDS DAM includes clarifications to old instructions, expansion of instructions, new instructions, new data items, new terminology, new reportable cancers, no longer reportable cancers, a new records layout, new requirements for SSDIs, New Codes for existing data items, and many more changes to the 2021 FCDS DAM. We encourage users to review the entire FCDS DAM to ensure they have captured the latest updates and revisions including Appendix P – Resources for Registrars. This is only a Summary of Changes and does not include every single revision in the manual – only major change points. Thank You.

- MOST CHANGES APPEAR IN RED TYPE, BLUE TYPE, OR HIGHLIGHTED SECTIONS – and described here
- Section I has many changes and clarifications – FCDS suggests every registrar read Section I carefully for changes.
- Section I has expanded Section explaining the Requirement for Reporting Non-Analytic Cases and Importance of These Cases
- Section I now has multiple statements describing that FCDS does not at this time allow or receive Update or Modify Records and cannot just update your abstracts when you make a change in your database. FCDS only receives the case from you once.
- Section I has an updated Comparison Table of Reportable Cancers – comparing CoC, SEER, and NPCR/FCDS Requirements.
- Section II has individual data item additions, revisions, updates, new codes, and some updated instructions.
- Section II has expanded the Date of Diagnosis and Definitive Terminology Sections to clarify frequently asked questions about using imaging dates as the Initial Date of DX, Mammography BIRADS and other xyz-RADS Classifications in imaging and how to use, and the need to prioritize Positive Terminology over Ambiguous Terminology on Imaging and how to know the difference.
- Appendix A has been updated to reflect the status of Florida Reporting Facilities in 2021.
- Appendix G has the Complete FCDS 2021 Record Layout including All New Data Items and All Core Data Items
- Appendix H has the Complete FCDS 2021 SSDI Requirements List
- Appendix O has both the abbreviated and the extended versions of the 2021 Casefinding List for Florida
- Appendix P has 2021 Resources for Registrars including all required manuals and references to abstract and code cases.
- Appendix P also has information about the FCDS Abstracting Basics Course Outline and Recommended Training Resources
- Appendix R has all the information about 2021 Updates to ICD-O-3 and How to Use Them

New Reportable Neoplasms

- Early or evolving melanoma, in situ and invasive – now reportable neoplasms
- ALL Gastrointestinal Stromal Tumors (GIST) – now reportable neoplasms
- Most Thymoma Tumors are now reportable neoplasms with Exceptions as Noted –
 - Exceptions include specific thymomas still classified as benign or borderline tumors
 - Exceptions include: microscopic thymoma, thymoma benign, micronodular thymoma with lymphoid stroms and ectopic hamartomatous thymomas.
- LCIS is still reportable to FCDS
- FCDS adopted the full ICD-O-3.2 as of 2018
- Please See Appendix R of the 2021 FCDS DAM for ALL 2021 Updates to ICD-O including Reportability Changes

ICDO3.2	Histology	Behavior	Level	Term	Code reference	obs
8580/3	8580	3	Preferred	Thymoma, NOS	(C37.9)	
8580/3	8580	3	Related	Intrapulmonary thymoma	(C34._)	
8580/3	8580	3	Related	Sclerosing thymoma	(C34._)	

APPENDIX S – Summary of Changes 2021

8580/3	8580	3	Related	Metaplastic thymoma	(C37.9)	
8581/3	8581	3	Preferred	Thymoma, type A	(C37.9)	
8581/3	8581	3	Synonym	Thymoma, medullary	(C37.9)	[obs]
8581/3	8581	3	Synonym	Thymoma, spindle cell	(C37.9)	[obs]
8582/3	8582	3	Preferred	Thymoma, type AB	(C37.9)	
8582/3	8582	3	Synonym	Thymoma, mixed type	(C37.9)	
8583/3	8583	3	Preferred	Thymoma, type B1	(C37.9)	
8583/3	8583	3	Synonym	Thymoma, lymphocyte-rich	(C37.9)	[obs]
8583/3	8583	3	Synonym	Thymoma, lymphocytic	(C37.9)	[obs]
8583/3	8583	3	Synonym	Thymoma, organoid	(C37.9)	[obs]
8583/3	8583	3	Synonym	Thymoma, predominantly cortical	(C37.9)	[obs]
8584/3	8584	3	Preferred	Thymoma, type B2	(C37.9)	
8584/3	8584	3	Synonym	Thymoma, cortical	(C37.9)	[obs]
8585/3	8585	3	Preferred	Thymoma, type B3	(C37.9)	
8585/3	8585	3	Synonym	Thymoma, atypical	(C37.9)	[obs]
8585/3	8585	3	Synonym	Thymoma, epithelial	(C37.9)	[obs]

No Longer Reportable Neoplasms

- Non-invasive follicular thyroid neoplasm with papillary like nuclear features (NIFTP) is a low grade tumor of the thyroid gland and is no longer reportable.
- Dermatofibrosarcoma protuberans has been reclassified as benign/borderline malignancy and is no longer reportable
- Some Immature Teratoma Cases (lung, thymus, thyroid) are no longer classified malignant and are no longer reportable
- Several Cutaneous Lymphoid Diseases have been reclassified as borderline malignancy and are no longer reportable
 - Primary Cutaneous CD4-Positive Small/Medium T-cell Lymphoma
 - Primary Cutaneous CD30_ T Cell Lymphoproliferative Disorder
 - Hydroa Vaccinoforme-like lymphoproliferative disorder
 - Langerhans Cell Histiocytosis, NOS
 - Polymorphic Post Transplant Lymphoproliferative Disorder (PTLD)
- Follicular Tumor of Undertain Malignant Potential/Follicular Carcinoma, Encapsulated

New Data Items Required

Item #	FCDS / NAACCR Item Name
1068	Grade Post Therapy Clin (yc)
2232	Name - Birth Surname
2315	Medicare Beneficiary Identifier
3838	Gleason Patterns Clinical
3839	Gleason Patterns Pathological
3840	Gleason Score Clinical
3841	Gleason Score Pathological
3842	Gleason Tertiary Pattern

Retired FCDS Date Items – No Longer Required for Any Cases/Any Years

Item #	FCDS / NAACCR Item Name
880	TNM Path T
890	TNM Path N
900	TNM Path M

APPENDIX S – Summary of Changes 2021

910	TNM Path Stage Group
920	TNM Path Descriptor
930	TNM Path Staged By
940	TNM Clin T
950	TNM Clin N
960	TNM Clin M
970	TNM Clin Stage Group
980	TNM Clin Descriptor
990	TNM Clin Staged By
1060	TNM Edition Number
2390	Name--Maiden

FCDS Required SSDI's

Item #	FCDS/NAACCR Item Name	Start Date
3800	Schema ID	2018
3816	Brain Molecular Markers	2018
3817	Breslow Tumor Thickness	2018
3827	Estrogen Receptor Summary	2018
3835	Fibrosis Score	2018
3838	Gleason Patterns Clinical	2021
3839	Gleason Patterns Pathological	2021
3840	Gleason Score Clinical	2021
3841	Gleason Score Pathological	2021
3842	Gleason Tertiary Pattern	2021
3843	Grade Clinical	2018
3844	Grade Pathological	2018
1068	Grade Post Therapy Clin (yc)	2021
3845	Grade Post Therapy Path (yp)	2018
3855	HER2 Overall Summary (breast, esophagus, stomach)	2018
3890	Microsatellite Instability (MSI)	2018
3915	Progesterone Receptor Summary	2018
3920	PSA (Prostatic Specific Antigen) Lab Value	2018
3932	LDH Pretreatment Lab Value	2018

Existing Data Items With New Codes or Updated Instructions

- ITEM # 1506 – Phase I Radiation Treatment Modality – New Codes/Updated Definitions

98	Radiation treatment administered; modality unknown – NEW CODE
99	Unknown if radiation treatment administered – ONLY FOR DEATH CERTIFICATE CASES

- ITEM # 830 – Regional Lymph Nodes Examined
- ITEM # 820 Regional Lymph Nodes Positive
- ITEM # 1292 Scope of Regional Node Surgery

The above 3 Regional Lymph Node Items have been modified to recognize that FNA or core biopsy of a regional lymph node should not be coded as a regional lymph node removed, nor should it be counted as ‘treatment’ in the various Treatment EDITS as surgery.

Therefore, when the Scope of Regional Lymph Node Surgery is coded = 1 (FNA, core biopsy), this is no longer considered surgery in the Treatment Status Field or Sequence of Surgery to XRT or Systemic Therapy Fields. And, the Regional Lymph Nodes Examined should = 95 for all of these cases. However, the Regional Lymph Nodes Positive may be coded as either 00 or 95 depending on the result. Code 95 when the result of the FNA/Core Biopsy is positive. Code 00 when the result of the FNA/Core Biopsy is negative.

- All Treatment Items – FCDS will no longer allow the Treatment Codes to = 9 or 99. Enter 0 or 00 rather than 9 or 99 if unknown.

APPENDIX S – Summary of Changes 2021

- Exceptions to Allow Coding of 9 in Scope of Regional Lymph Node Surgery or 98 in Surgery of Primary Site is for leukemia, lymphoma, brain tumors, myelodysplastic syndromes and myeloproliferative diseases – plus the unknown and ill-defined sites that require specific codes in these fields.
- Scope of Regional Lymph Node Surgery = 9
 - Primary Site: C420, C421, C423, C424, C700-C709, C710-C729, C751-C753, C761,-C768, C809
 - Lymphoma (M-9590-9726, 9728-9732, 9734-9740, 9750-9762, 9811-9831, 9940, 9948, 9971) with Lymph Node Primary Site C77.0-C77.9)
 - Unknown or Ill-defined Primary Site (C76.0-C76.8, C80.9)
 - Hematopoietic, reticuloendothelial, Immunoproliferative, or myeloproliferative disease (9727, 9733, 9741, 9742, 9764, 9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9993)
- FCDS no longer accepts an unknown Date of Diagnosis – the date must be estimated if unknown – see the Instructions under Date of Initial Diagnosis for handling unknown or partial dates in these cases. This includes Historical Grid Cases – no unknown.

NEW Histological Terms and New Histological Terms – Appendix R

ICD-O Code	Term/site
8273/3	Pituitary blastoma/ Embryoma
9749/3	Erdhiem-Chester Disease
9766/3	Lymphomatoid granulomatosis, grade 3
9819/3	B-lymphocytic leukemia/lymphoma, BCR-ABL1-like
9877/3	Acute myeloid leukemia with mutated NPM1
9878/3	Acute myeloid leukemia with biallelic mutations of CEBPA
9879/3	Acute myeloid leukemia with mutated RUNX1
9912/3	Acute myeloid leukemia with BCR-ABL1
9968/3	Myeloid/lymphoid neoplasms with PCM1-JAK2
9993/3	Myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia
9715/3	Anaplastic large cell lymphoma ALK-negative Breast implant-associated anaplastic large cell lymphoma

Histology Codes No Longer Used for ICD-O-3.2 – OBSOLETE CODES – Appendix R

ICD-O-3/3.1 Code/behavior	Histological Term(s)
8471/3	Papillary mucinous cystadenocarcinoma (C56.9) Papillary pseudomucinous cystadenocarcinoma (C56.9)
9150/3	Hemangiopericytoma, malignant
9260/3	Ewing sarcoma
9670/3	Malignant lymphoma, small B lymphocytic, NOS (<i>see also M-9823/3</i>) Malignant lymphoma, lymphocytic, diffuse, NOS Malignant lymphoma, lymphocytic, NOS Malignant lymphoma, lymphocytic, well differentiated, diffuse Malignant lymphoma, small cell diffuse Malignant lymphoma, small cell, NOS Malignant lymphoma, small lymphocytic, diffuse Malignant lymphoma, small lymphocytic, NOS
9728/3	Precursor B-cell lymphoblastic lymphoma (<i>see also M-9836/3</i>)
9729/3	Precursor T-cell lymphoblastic lymphoma (<i>see also M-9837/3</i>)
9826/3	Burkitt cell leukemia (<i>see also M-9687/3</i>)

APPENDIX S – Summary of Changes 2021

	Acute leukemia, Burkitt type [obs] Acute lymphoblastic leukemia, mature B-cell type B-ALL [obs] FAB L3 [obs]
9836/3	Precursor B-cell lymphoblastic leukemia (<i>see also M-9728/3</i>) c-ALL Common ALL Common precursor B ALL Pre-B ALL Pre-pre-B ALL Pro-B ALL
9991/3	Refractory neutropenia
9992/3	Refractory thrombocytopenia